MCL-1 has also emerged as an important resistance factor to BCL-2/BCL-XL specific BH3-mimetics in hematopoietic cancers, encouraging the investigation of combinatorial treatments to also target MCL-1. Here, MCL1 is linked to hematopoietic and lymphoid cell neoplasm.